Positive Phase 1 data for DA-1726 shows competitive weight loss and encouraging liver signals, potentially supporting future partnering or financing. With a $15M market cap and 88% analyst bullish consensus, any positive catalyst can move shares significantly. Monitor upcoming titration study data and cash runway updates.
Price Chart
Executive Summary
MetaVia Inc. (MTVA) disclosed Phase 1 data for DA-1726 at EASL 2026. The 48 mg cohort showed up to 9.1% mean body weight reduction at Day 54 without plateaus and exploratory FibroScan improvements in liver biomarkers. The drug was generally well tolerated with no serious adverse events. This is an early-stage data update for a $15M market cap biotech with no revenue.
Key Facts
- 48 mg cohort achieved up to 9.1% mean body weight reduction at Day 54 without evidence of plateau
- Mean weight reduction was 6.1% at Day 26 and 9.1% at Day 54 (p < 0.05 vs placebo at Day 26)
- No serious adverse events or treatment-related discontinuations in the 48 mg cohort
- FibroScan improvements: CAP -20.0 dB/m in 48mg group vs +24.0 dB/m placebo; liver stiffness -10.3% vs +13.8% placebo
- Ongoing Phase 1 Part 3a/3b titration studies evaluating extended higher-dose treatment
Financial Impact
No financial figures disclosed; early-stage biotech with no revenue. Positive clinical data may de-risk pipeline and affect financing outlook.
Risk Factors
- Phase 1 data in only 9 subjects (6 in extension phase) — limited sample size
- No evidence of plateau is promising but data only goes to Week 8; longer-term durability unproven
- Highly competitive GLP-1/glucagon agonist space (Eli Lilly, Novo Nordisk, etc.)
- Micro-cap biotech with no revenue — reliant on capital markets for funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-066631 |
| Document: mtva-20260527xex99d1.htm | 0001104659-26-066631 |
| Document: 0001104659-26-066631-index-headers.html | 0001104659-26-066631 |
| Document: 0001104659-26-066631-index.html | 0001104659-26-066631 |
| Document: 0001104659-26-066631.txt | 0001104659-26-066631 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 3 | $1.36 | awaiting T+20 | — | $1.15 (−15.07%) |
Oct 13, 2026 14d ago | 8-K | $1.43 | awaiting T+20 | — | $1.15 (−19.23%) |
Sep 9, 2026 6w ago | 8-K | $1.74 $1.46 | ▼ −16.09% | ▼ −18.04% | $1.15 (−33.62%) |
Jul 9, 2026 15w ago | 8-K | $1.73 $1.45 | ▼ −16.18% | ▼ −18.43% | $1.15 (−33.24%) |
Jul 2, 2026 16w ago | 424B5 | $1.48 $1.44 | ▲ +2.70% | ▲ +2.29% | $1.15 (+21.96%) |
Jun 8, 2026 20w ago | 8-K | $1.89 $1.58 | ▼ −16.40% | ▼ −17.85% | $1.15 (−38.89%) |
Jun 8, 2026 20w ago | 8-K | $2.22 $1.51 | ▼ −31.98% | ▼ −33.61% | $1.15 (−47.97%) |
May 27, 2026 21w ago | 8-K | $3.34 $1.53 | ▼ −54.19% | ▼ −52.29% | $1.15 (−65.42%) |
May 18, 2026 23w ago | 8-K | $1.11 $1.65 | ▲ +48.65% | ▲ +47.07% | $1.15 (+4.05%) |
May 14, 2026 23w ago | 8-K | $1.11 $1.71 | ▲ +54.05% | ▲ +51.94% | $1.15 (+4.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers